Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

Cancer Advances

Status and phase: Completed; Phase 2

Conditions: Jaundice; Pancreatic Cancer

Treatments: Drug: G17DT

Study type: Interventional

Funder types: Industry

Identifiers

NCT02098239

PC2

Details and patient eligibility

About

The study was designed to assess the effect of jaundice on the ability of G17DT to generate antibodies before and after treatment of biliary obstruction due to advances pancreatic cancer.

Full description

Jaundiced patients with advanced pancreatic cancer (either locally, advanced or metastatic) were treated with G17DT either immediately (Group A), or following biliary stenting when jaundice had resolved (Group B). Patients not jaundiced at time of presentation were to enter Group B. Patients received 3 Intramuscular injections of G17DT at weeks 0, 1, and 3. A booster injection was offered to patients who had measurable anit-G17Dt antibodies but had anti-G17DT antibodies that fell below a pre-specified threshold after week 23. Patients were evaluated until study closure ort until patient death.

Enrollment: 41 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a pancreatic adenocarcinoma (cytologically or histologically proven), not suitable for a potentially curative resection.
• If patients were jaundiced, bilirubin had to be >80 μmol/L.
• Male or female patients over 18 years of age.
• World Health Organization (WHO) performance status of 0 to 2.
• Patients with a life expectancy of at least 8 weeks.
• Patients must have given written informed consent.

Exclusion criteria

• Patients undergoing a potentially curative resection.
• Jaundiced patients with a bilirubin value <80 μmol/L.
• Patients not considered fit for endoscopic or percutaneous biliary stenting.
• Patients receiving any other anti-cancer therapy.
• History of other malignant disease except non-melanomatous skin cancer or in situ carcinoma of the cervix.
• Females who were pregnant, planning to become pregnant, or who were lactating.
• Patients taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or during this study.
• Previous G17DT treatment.
• Haematological indicators:

Haemoglobin (Hb) <10.0 g/dL. White cell count (WCC) <4.0×109/L. Platelets <100×109/L.

Trial design

41 participants in 2 patient groups

Group A

Active Comparator group

Description:

Jaundiced patients with bilirubin value \>80 μmol/L. Received G17DT immediately prior to biliary stenting.

Treatment:

Drug: G17DT

Group B

Active Comparator group

Description:

Patients to be treated following biliary decompression or for immediate treatment if non-jaundiced. Received G17DT 2 weeks after biliary stenting when bilirubin was \<40 μmol/L.

Treatment:

Drug: G17DT